Manufacturers report negative results for serlopitant in prurigo nodularis studies

In both the MTI-105 and MTI-106 Phase III studies this once daily, oral, NK1 receptor antagonist failed to improve pruritus (worst itch numerical rating score) vs placebo.

Source:

PharmaTimes